home / stock / aezs / aezs quote
Last: | $8.52 |
---|---|
Change Percent: | -1.1% |
Open: | $8.6799 |
Close: | $8.52 |
High: | $8.6799 |
Low: | $8.51 |
Volume: | 5,647 |
Last Trade Date Time: | 05/17/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$8.52 | $8.6799 | $8.52 | $8.6799 | $8.51 | 5,647 | 05-17-2024 |
$8.5858 | $8.6299 | $8.5858 | $8.8 | $8.3754 | 12,084 | 05-16-2024 |
$8.645 | $8.5386 | $8.645 | $8.83 | $8.3999 | 16,957 | 05-15-2024 |
$8.3885 | $8.1 | $8.3885 | $8.53 | $8.0101 | 12,434 | 05-14-2024 |
$8.3992 | $8.17 | $8.3992 | $8.48 | $8 | 17,234 | 05-13-2024 |
$8.23 | $7.81 | $8.23 | $8.23 | $7.81 | 9,851 | 05-10-2024 |
$7.84 | $8.08 | $7.84 | $8.1392 | $7.83 | 11,956 | 05-09-2024 |
$7.8 | $8.09 | $7.8 | $8.13 | $7.8 | 6,382 | 05-08-2024 |
$8.03 | $8 | $8.03 | $8.34 | $7.9301 | 10,455 | 05-07-2024 |
$7.99 | $7.8 | $7.99 | $7.99 | $7.8 | 5,925 | 05-06-2024 |
$7.8 | $7.8 | $7.8 | $8.3487 | $7.74 | 19,914 | 05-03-2024 |
$2.01 | $2.14 | $2.01 | $2.14 | $1.96 | 20,503 | 05-02-2024 |
$2.09 | $1.95 | $2.09 | $2.15 | $1.95 | 81,023 | 05-01-2024 |
$1.95 | $1.95 | $1.95 | $2.07 | $1.95 | 19,325 | 04-30-2024 |
$1.9525 | $1.98 | $1.9525 | $1.98 | $1.95 | 4,337 | 04-29-2024 |
$1.9562 | $1.965 | $1.9562 | $1.965 | $1.95 | 5,110 | 04-26-2024 |
$1.96 | $1.96 | $1.96 | $1.96 | $1.9501 | 11,719 | 04-25-2024 |
$1.97 | $1.96 | $1.97 | $2.01 | $1.96 | 1,455 | 04-24-2024 |
$1.97 | $2.02 | $1.97 | $2.02 | $1.96 | 2,736 | 04-23-2024 |
$1.955 | $1.95 | $1.955 | $1.99 | $1.95 | 24,162 | 04-22-2024 |
News, Short Squeeze, Breakout and More Instantly...
Aeterna Zentaris Inc. Company Name:
AEZS Stock Symbol:
NASDAQ Market:
TORONTO, ON, May 17, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“ Aeterna ” or the “ Company ”) announces that it has finalized certain details regarding the previously announced merger of equals transaction (the “ Tra...
Company ended the quarter with $29.5 million in cash DETECT-trial recruitment completed; Company continues to expect the completion of the trial in the second quarter and top-line data in the third quarter of 2024 All-stock merger of equals transaction with Ceapro Inc. exp...